Work Here?
Overview
SAB Biotherapeutics uses the DiversitAb platform to produce fully human polyclonal antibodies in genetically engineered transchromosomic cattle, removing the need for human donors. These antibodies are designed to treat immunology disorders and infectious diseases and include programs like SAB-142 for Type 1 Diabetes, SAB-176 for severe influenza, and SAB-195 for C. difficile infection. The platform can shorten development timelines, aiming to move candidates from concept to clinic in under five months, and it focuses on polyclonal antibodies rather than monoclonal ones. The company pursues regulatory approval and commercialization through collaborations with government agencies, academia, and pharmaceutical partners to address high-need diseases and biodefense applications.
About SAB
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
IPO
Headquarters
Sioux Falls, South Dakota
Founded
2014
Get referred to SAB
See people who can refer or advise you
Simplify's Take
What believers are saying
- May 12, 2026: SAFEGUARD enrollment stayed on track for completion by end-2026.
- July 21, 2025: Sanofi joined SAB BIO's oversubscribed $175 million private placement.
- April 29, 2026: Emergent BioSolutions secured SAB-142 process development and manufacturing capacity.
What critics are saying
- SAB-142 data arrives in 2H 2027; failure ends SAB BIO's only near-term value driver.
- March 2026 dilution and July 2025 warrants pressure shares for years.
- No approved products and $34.4 million 2025 R&D burn keep reliance on financing relentless.
What makes SAB unique
- SAB BIO's DiversitAb platform uses transchromosomic cattle to generate fully human polyclonal antibodies.
- SAB-142, SAB-176, and SAB-195 share one antibody-engineering platform across diseases.
- March 2026 and April 2026 manufacturing agreements keep development and scale-up in-house.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$666.9M
Above
Industry Average
Funded Over
12 Rounds
Benefits
Hybrid Work Options
Stock Price
Growth & Insights and Company News
6 month growth
↑ 2%1 year growth
↓ -1%2 year growth
↓ -2%SAB Biotherapeutics prices $85M stock offering at $3.85/share
SAB Biotherapeutics has launched an underwritten public offering of common stock and pre-funded warrants. The company is offering securities directly, with underwriters having the option to purchase up to 15% additional securities within 30 days. Proceeds will primarily fund development of SAB-142, the company's lead candidate for Type 1 Diabetes. The funds will also support clinical trials, manufacturing, regulatory activities and general corporate expenses. Shares fell 6.9% in post-market trading following the announcement.
SAB Biotherapeutics has reported full year 2025 financial results whilst advancing its lead candidate SAB-142 for type 1 diabetes. The company raised $175 million in an oversubscribed private placement including strategic investor Sanofi, providing operational runway through 2028. SAB has dosed multiple patients in its registrational Phase 2b SAFEGUARD study, with enrollment on track to complete by end of 2026 and topline data expected in second half of 2027. Phase 1 data released in December 2025 confirmed SAB-142's favourable safety profile, showing no serum sickness and low immunogenicity across all cohorts. The company ended 2025 with cash and securities of $143.5 million. Research and development expenses were $34.4 million, up from $30.3 million in 2024.
SAB Biotherapeutics announced an oversubscribed $175 million private placement with participation from Sanofi and other investors. The funds will support the Phase 2b SAFEGUARD study of SAB-142 for autoimmune T1D and extend the cash runway to mid-2028. The deal includes issuing Series B nonvoting convertible preferred stock and warrants for potential additional proceeds of $284 million. The private placement is expected to close on July 22, 2025, subject to conditions.
SAB BIO Announces Oversubscribed $175 Million Private Placement...
SAB is Hiring for 4 Jobs on Simplify!
Find jobs on Simplify and start your career today
About SAB
Industries
Biotechnology
Healthcare
Company Size
51-200
Company Stage
IPO
Headquarters
Sioux Falls, South Dakota
Founded
2014
SAB is Hiring for 4 Jobs on Simplify!
Find jobs on Simplify and start your career today